Pfizer Inc

NYSE: PFE
$25.88
+$0.11 (+0.4%)
Real Time Data Delayed 15 Min.

PFE Articles

One strategy that has been popular each year as investors rebalance and make changes is the so-called Dogs of the Dow.
Disney, Pfizer, General Electric, and McDonald's weighed on the DJIA Wednesday.
Pfizer has just raised its payout by about 6% and more than doubled what it already had on its buyback plans.
Intel, Microsoft, Pfizer, and United Technologies drove the DJIA higher Friday.
Shares of Pfizer appeared to be headed for a new high after the company announced that the FDA had approved its treatment for adult patients with active psoriatic arthritis.
Cellectis saw its shares make a handy gain early on Wednesday after the firm announced preliminary data from its two Phase 1 studies in conjunction with Pfizer.
The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
Apple, Disney, Merck, and Pfizer were the leading gainers among the Dow 30 stocks on Monday. Bitcoin settled up 23% after its first trading session.
A generic version of Viagra is coming to America, but will existing customers be willing to switch over to a generic version of the pill?
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
Disney, Intel, Pfizer, and Verizon led Tuesday's drop in the DJIA.
One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be “deep value” plays at Merrill Lynch.
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
When Pfizer released its third-quarter earnings report before the markets opened on Tuesday, the results and guidance lived up to what analysts expected but weren't enough to placate investors.